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In late 2013, a focus group met to participate in the Orofacial Pain Team Workshop, held 
in Montreal, Canada, where the issue of appropriate opioid analgesic prescribing for pain 
by Canadian dentists was discussed. There was agreement that the use of opioid 
analgesics by dentists for either acute or chronic orofacial pain conditions has not been 
investigated satisfactorily in this country. 
A number of questions related to the use of opioid analgesics by dentists were raised by 
the focus group: How well do dentists manage post-operative pain? How often do 
patients report inadequate analgesia after dental surgery? How often are opioid analgesics 
prescribed and for which procedures? Do dentists overprescribe? Do they instruct their 
patients about the risks related to leftover doses? Do dentists monitor the use of opioid 
analgesics by their patients and, if so, how does monitoring vary in urban compared to 
rural areas? Is opioid use different in underserved populations? What are the risk factors 
for problematic use? What is the current level of knowledge about the use of opioid 
analgesics in populations thought to be more vulnerable to misuse or abuse? 
Opioid analgesic prescribing for acute dental pain 
The existing literature suggests that the use of opioid analgesics for acute procedural pain 
varies significantly in different countries. In the UK in 2001, of all prescriptions for 
analgesics written by dentists, the most commonly prescribed analgesic was ibuprofen, 
representing 73% of prescriptions. The only commonly prescribed opioid analgesic was 
codeine, which represented only 19% of prescriptions.1 One of the most studied acute 
surgical procedures in dentistry is third molar extraction. Meta-analyses indicate that 
NSAIDs, like ibuprofen, show the best evidence for efficacy for pain post-extraction 
(roughly 80% of patients given 600 mg ibuprofen had >50% pain relief), consistent with 
the use of ibuprofen by UK dentists.1,2 Use of codeine (60 mg) with acetaminophen (650 
mg) is less likely to produce significant pain relief post-extraction, and is associated with 
a much greater incidence of adverse effects.1 
In contrast to the modest prescribing rate of opioid analgesics by UK dentists, in the US, 
12% of all immediate release opioid analgesic prescriptions are written by dentists (just 
slightly less than family physicians).3 An American Dental Association survey from 2006 
suggested that while a majority of oral and maxillofacial surgeons (74%) preferred 
patients to use ibuprofen afterthird molar extraction, 85% also prescribed an opioid 
analgesic post-procedure (most commonly hydrocodone or oxycodone). 3 Prescribing 
patterns after oral surgical or endodontic treatments at a dental clinic at the University of 
Alabama indicated about 80% of patients received a prescription for an opioid analgesic 
(most commonly hydrocodone or oxycodone in combination with acetaminophen).4 The 
most common procedure that resulted in a prescription for an analgesic was tooth 
extraction, but only 1% of prescriptions for tooth extraction-related pain were for 
NSAIDs, while over 90% of these patients received a prescription for an opioid 
analgesic.4 
Of concern, this study also noted that patients over the age of 45 were more likely to 
receive an opioid analgesic prescription than younger patients, and about 25% of patients 
attending the clinic were not prescribed any analgesic after an invasive procedure that 
would be expected to cause pain.4 Moreover, the higher prescribing rate of opioid 
analgesics for dental pain in the US is not confined to dental health providers. A study of 
prescribing of opioid analgesics by physicians in a US hospital emergency department for 
painful dental conditions found that roughly 60% of patients were discharged with a 
prescription for an opioid analgesic.5 
Most dentists do not screen patients for past history of abuse or misuse prior to 
prescribing an opioid analgesic. Surveys of dentists and maxillofacial surgeons indicate 
that an average of 20 doses of an opioid analgesic (commonly hydrocodone or 
oxycodone) are prescribed post-procedure and most dentists expect patients to have 
leftover analgesics.4, 6 Particularly concerning was the expectation by dentists that many 
patients given prescriptions for opioid analgesics would not require all of the doses 
dispensed.4, 6 It is thought that unused opioid analgesics are a significant source of 
misused drugs.3 The risk of misuse of leftover opioid analgesics by younger individuals is 
of particular concern.3 
Greater collaboration between Canadian dentists and pharmacists is needed to address 
this problem. One potential solution to prevent inadvertent overprescribing of opioid 
analgesics is to have dentists write prescriptions for fewer initial doses. Instead, dentists 
could arrange for additional doses as needed, to be filled at the discretion of a pharmacist. 
Dentists should avoid prescribing opioid analgesics if patients are already on a 
benzodiazepine or have a known history of misuse of these drugs and should be available 
to return pharmacist's calls rapidly if a problem occurs at renewal time.7 
Opioid analgesic prescribing for chronic non-cancer orofacial pain 
It is unclear how often Canadian dentists or family physicians use opioid analgesics for 
the treatment of moderate to severe chronic non-cancer orofacial pain conditions such as 
temporomandibular disorders (TMDs) and neuropathies. Dentists, in particular, may not 
feel confident prescribing or monitoring opioid analgesics for these chronic pain 
conditions. There is also little evidence that supports the use of opioid analgesics for the 
treatment of chronic orofacial pain (Table 1). Nevertheless, the use of opioid analgesics 
for chronic TMDs pain that has not responded adequately to all other treatments (i.e., 
physical therapy, cognitive and behavioural therapy, NSAIDs such as ibuprofen or 
diclofenac, antidepressants such as nortriptyline or duloxetine, and antiepileptics such as 
gabapentin) may be warranted.  However, evidence indicates that only a subgroup of 
patients will find opioid analgesics effective over months or years, and of these, 50% will 
have adverse effects that will lead many to discontinue their use.8, 9 Thus, it is 
recommended that initiation of opioid analgesic therapy be done on a trial basis and re-
evaluated frequently (Table 1). 
Table 1: Opioid prescription for chronic, non-malignant orofacial pain* 
Proper Patient Selection 
1. Consider opioid prescription for patients with neuropathic pain, 
temporomandibular disorders,** atypical facial pain,** rheumatoid arthritis, 
neck pain, headache.** 
2. Consider a trial when pain is moderate to severe (>4/10), has an adverse effect 
on function or quality of life, and when patients have not responded to non-
opioid analgesic therapies or to opioid analgesic therapy with codeine or 
tramadol. 
3. Consider patient's medical history, including general medical history, current 
medications (prescription and over-the-counter drugs), recreational drug use 
(alcohol, cannabis, etc.), psychosocial history (information related to 
employment and support network, including friends and family), dental exam 
(including appropriate diagnostic tests and assessment of type(s) of pain), risk 
assessment (history of abuse, misuse or addiction and occurrence of other 
conditions such as sleep apnea), and benefit-to-harm analysis. 
Consent and Management of Therapy 
1. Obtain verbal or written informed consent from patient. 
2. Discuss and document initial and ongoing monitoring of goals, expectations, 
risk-benefit (including side effects) and alternatives. 
3. Initiate a short-term therapeutic trial, reassess need periodically. 
4. Individualize treatment "start low, go slow" (immediate release opioid 
analgesic preferred for titration, low initial dosing and titration, regular dosing 
with allowance of as needed doses for breakthrough) based on health, previous 
exposure to opioid analgesics, attainment of goals, and incidence of adverse 
effects. 
5. Avoid concomitant benzodiazepines, if currently using, decrease dose slowly to 
permit discontinuation.                
6. Monitor efficacy regularly to ensure optimum pain management (available 
tools include the McGill Pain Questionnaire13, Brief Pain Inventory) 
7. Consider periodic urine drug screens in patients at risk for misuse or aberrant 
behavior. 
8. Manage adverse effects as required (e.g., constipation is common, decreased 
libido/sexual dysfunction (less common), sleep apnea (less common), 
hyperalgesia is rare. 
9. Caution that cognitive impairment may affect driving and work safety. 
10. Maintain detailed records (include reasons for continued use). 
*Based on criteria from previously published guidelines.10-12 
**Indicates a lack published evidence for opioid agonist efficacy.  
  
Long-term opioid treatment of chronic nonmalignant orofacial pain: 
unproven efficacy and neglected safety? 
The focus group suggested that future prospective studies should be conducted to assess 
management of acute, post-operative and chronic orofacial pain in Canada. Such studies 
should include quantitative and qualitative measures of pain as well as measures of 
psychosocial factors and addiction risk.7,10 These studies should include evaluations at 
least 6 months after an operation in order to determine the prevalence of persistent post-
operative pain and to evaluate the efficacy of sustained use of opioid analgesics to treat 
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